Seven growth hormone-deficient children with hypothalamic-origin deficiency responded to intravenous GHRH with growth hormone release, but when given continuous subcutaneous GHRH for six months or more, only two showed meaningful growth improvement. In contrast, switching to daily recombinant human growth hormone therapy produced robust catch-up growth in all patients, with an average growth rate of 8.5 cm per year. The study concludes that GHRH therapy cannot yet be recommended over direct growth hormone treatment for routine management of growth hormone deficiency in children.
Butenandt, O; Staudt, B